Meeting
2020 Genitourinary Cancers Symposium
A systematic review and network meta-analysis of first-line treatment options in patients metastatic renal cell carcinoma.
Authors
Irbaz Bin Riaz
Mayo Clinic, Rochester, MN
Irbaz Bin Riaz , Alexander J. Ryu , Yuan Yao , Rabbia Siddiqi , Jessey Mathew , Qurat Ul Ain Riaz Sipra , Haris Zahoor , Zhen Wang , M. Hassan Murad , Lance C. Pagliaro , Brian Addis Costello
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 709)
Abstract #
709
Poster Bd #
H7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Infusion-related reactions with immune checkpoint inhibitors in genitourinary cancers: A systematic review and meta-analysis.
First Author: Yu Fujiwara
Poster
2023 ASCO Genitourinary Cancers Symposium
Efficacy of immune-checkpoint inhibitor (ICI) combination as a first-line (1L) therapy in metastatic renal cell carcinoma (mRCC) with sarcomatoid histology: A systematic review and meta-analysis.
First Author: Rabbia Siddiqi
Poster
2021 Genitourinary Cancers Symposium
A framework for living evidence synthesis in cancer: Living, interactive network meta-analysis for first-line treatment of metastatic renal cell carcinoma (mRCC).
First Author: Irbaz Bin Riaz
Poster
2017 Genitourinary Cancers Symposium
A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
First Author: David F. McDermott